Liver Cirrhosis - Pipeline Review, H2 2012 - This report 'Liver Cirrhosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Liver Cirrhosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Cirrhosis. Liver Cirrhosis - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Liver Cirrhosis.
- A review of the Liver Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Liver Cirrhosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Liver Cirrhosis Overview
Therapeutics Development
An Overview of Pipeline Products for Liver Cirrhosis
Liver Cirrhosis Therapeutics under Development by Companies
Liver Cirrhosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Liver Cirrhosis Therapeutics – Products under Development by Companies
Liver Cirrhosis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Liver Cirrhosis Therapeutics Development
Shenzhen Beike Biotechnology Co., Ltd.
Stelic Institute & Co.
PharmaIN Corporation
Stempeutics Research Private Limited
Liver Cirrhosis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
STNM-04 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous CD133 + Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lenograstim + Haematopoietic Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
zinc acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bone Marrow Derived CD133+ Stem Cells Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
umbilical cord mesenchymal stem cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allogeneic Bone Marrow Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Bone Marrow Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Umbilical Cord Mesenchymal Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Umbilical Cord Mesenchymal Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
olmesartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Bone Marrow Derived Endothelial Progenitor Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stempeucel-LC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bone Marrow Derived Stem Cells Transplantation + G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pioglitazone + Mesenchymal Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sapropterin dihydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-CSF + Peripheral Blood Mononuclear Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F-351 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Undisclosed Peptide For Liver Cirrhosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thrombopoietin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Umbilical Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liver Cirrhosis Therapeutics – Drug Profile Updates
Liver Cirrhosis Therapeutics – Discontinued Products
Liver Cirrhosis Therapeutics - Dormant Products
Liver Cirrhosis – Product Development Milestones
Featured News & Press Releases
Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy
Aug 03, 2012: Otsuka Pharma Files For Additional Indication For Samsca Tablets For Treatment Of Fluid Retention Associated With Cirrhosis Of Liver
Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis
May 29, 2012: Ocera Therapeutics Announces Preliminary Data From Phase II Study Of OCR-002 For Treatment Of Cirrhosis Of Liver And Upper GI Bleeding
Oct 29, 2009: LG Life Sciences Discovers Innovative Necrosis Inhibitors
Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNI's Key Therapeutic Product for Liver Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Liver Cirrhosis, H2 2012
Products under Development for Liver Cirrhosis – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Shenzhen Beike Biotechnology Co., Ltd., H2 2012
Stelic Institute & Co., H2 2012
PharmaIN Corporation, H2 2012
Stempeutics Research Private Limited, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Liver Cirrhosis Therapeutics – Drug Profile Updates
Liver Cirrhosis Therapeutics – Discontinued Products
Liver Cirrhosis Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Liver Cirrhosis, H2 2012
Products under Development for Liver Cirrhosis – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012 30
